[go: up one dir, main page]

IN2012MU03723A - - Google Patents

Download PDF

Info

Publication number
IN2012MU03723A
IN2012MU03723A IN3723MU2012A IN2012MU03723A IN 2012MU03723 A IN2012MU03723 A IN 2012MU03723A IN 3723MU2012 A IN3723MU2012 A IN 3723MU2012A IN 2012MU03723 A IN2012MU03723 A IN 2012MU03723A
Authority
IN
India
Prior art keywords
ticagrelor
intermediates
preparation
substantially eliminates
potential impurities
Prior art date
Application number
Other languages
English (en)
Inventor
Vijayavitthal Thippannachar Mathad
Navnath Chintaman Niphade
Gorakshanath Balasaheb Shinde
Santosh Ambadas Padaki
Pravin Keshav Mahale
Original Assignee
Megafine Pharma P Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megafine Pharma P Ltd filed Critical Megafine Pharma P Ltd
Priority to IN3723MU2012 priority Critical patent/IN2012MU03723A/en
Priority to PCT/IN2013/000812 priority patent/WO2014102830A1/fr
Publication of IN2012MU03723A publication Critical patent/IN2012MU03723A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ceramic Products (AREA)
IN3723MU2012 2012-12-31 2013-12-30 IN2012MU03723A (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN3723MU2012 IN2012MU03723A (fr) 2012-12-31 2013-12-30
PCT/IN2013/000812 WO2014102830A1 (fr) 2012-12-31 2013-12-30 Procédé de préparation de ticagrelor et de ses intermédiaires

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3723MU2012 IN2012MU03723A (fr) 2012-12-31 2013-12-30

Publications (1)

Publication Number Publication Date
IN2012MU03723A true IN2012MU03723A (fr) 2015-07-10

Family

ID=50097795

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3723MU2012 IN2012MU03723A (fr) 2012-12-31 2013-12-30

Country Status (2)

Country Link
IN (1) IN2012MU03723A (fr)
WO (1) WO2014102830A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CZ2013866A3 (cs) * 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
WO2016030704A1 (fr) * 2014-08-30 2016-03-03 Cipla Limited Forme solide d'intermédiaire de ticagrelor
CN105481861B (zh) * 2014-09-19 2018-04-17 北京普禄德医药科技有限公司 一种血小板聚集抑制剂及其制备方法和用途
CN105503876B (zh) * 2014-09-24 2017-09-05 海门慧聚药业有限公司 替卡格雷的制备方法
CN105859720A (zh) * 2015-01-20 2016-08-17 上海方楠生物科技有限公司 一种替格瑞洛溶液的制备方法
WO2016128996A2 (fr) * 2015-02-14 2016-08-18 Strides Shasun Limited Procédé amélioré de préparation du ticagrelor et intermédiaires correspondants
CN105153167B (zh) * 2015-09-06 2017-09-19 惠州信立泰药业有限公司 一种替格瑞洛结晶及含有该结晶的药物组合物
CN105669681A (zh) * 2016-04-11 2016-06-15 成都华宇制药有限公司 一种替格瑞洛的合成方法
CN106543191B (zh) * 2016-10-28 2019-03-01 天津红日药业股份有限公司 一种替格瑞洛制备工艺
CN108892670B (zh) * 2018-07-12 2019-12-20 江西国药有限责任公司 一种高纯度替格瑞洛的制备方法
CN110437237A (zh) * 2019-09-06 2019-11-12 上海汇伦生命科技有限公司 一种1,2-二醇化合物单一结晶的制备方法
CN110684019B (zh) * 2019-10-29 2020-08-18 株洲千金药业股份有限公司 一种替格瑞洛中间体氧化物杂质的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702773D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
AU2009292269B2 (en) * 2008-09-09 2012-11-01 Astrazeneca Ab A process for preparing [1S- [1-alpha, 2-alpha, 3-beta (1S*, 2R*) 5-beta] ] -3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino] - 5- (propylthio) -3H-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates
JP2013500347A (ja) * 2009-07-27 2013-01-07 オースペックス ファーマシューティカルズ，インク． Ｐ２ｙ１２受容体のシクロプロピルモジュレーター

Also Published As

Publication number Publication date
WO2014102830A1 (fr) 2014-07-03

Similar Documents

Publication Publication Date Title
IN2012MU03723A (fr)
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2022000026A (es) Anticuerpos para tau.
EP2938616A4 (fr) Procédé de préparation de tofacitinib et d'intermédiaires
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MY192466A (en) Processes for the preparation of an apoptosis-inducing agent
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
IN2014DN09450A (fr)
IN2013MU00848A (fr)
IN2013MU01113A (fr)
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
PL2997144T3 (pl) Kompozycje enzymów do poprawy procesów fermentacji i ich produktów ubocznych
IN2014DN10209A (fr)
WO2014102759A3 (fr) Procédé de préparation de dasatinib et de ses intermédiaires
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
MX2014002378A (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
IN2014DN11218A (fr)
MX2015009565A (es) Proceso para elaborar derivados de magnolol.
IN2013MU03768A (fr)
IN2013CH05865A (fr)
EP2989097A4 (fr) Procédés améliorés pour la préparation de linézolide par utilisation de nouveaux intermédiaires
MX2014002630A (es) Produccion de alcaloides sin el aislamiento de compuestos intermediarios.
UA72478U (ru) Применение полентара как средства фригопротекторного действия